Aaron Tachibana, who holds the dual roles of Chief Financial Officer and Chief Operating Officer at Personalis, Inc. (NASDAQ: PSNL), filed reports on June 29, 2026, detailing transactions involving the company's equity. The filings outline a sequence of sales and acquisitions that reflect the mechanics of structured trading plans rather than spontaneous market decisions.
On the reported date, Tachibana disposed of 4,982 shares of Personalis common stock. The transaction occurred at a price of $14.00 per share, resulting in a total sale value of $69,748. This sale took place while the stock was trading near its 52-week high of $14.07. The equity has demonstrated substantial momentum, recording a 109% return over the preceding year. Despite this performance, data from InvestingPro suggests that PSNL may currently be trading at a premium relative to its estimated Fair Value.
Simultaneously, Tachibana acquired an equal number of shares, specifically 4,982 shares of common stock, at a price of $5.32 per share. This acquisition, totaling $26,504, was facilitated through the exercise of fully vested and exercisable stock options. The exercise price for these options was established at $5.32 per share.
Both the option exercise and the subsequent sale were executed in accordance with a Rule 10b5-1 trading plan. This pre-arranged framework was adopted by Tachibana on August 7, 2025, designed to facilitate the orderly management of insider equity holdings.
Following these transactions, Tachibana's direct holdings in Personalis common stock stand at 198,833 shares. Additionally, he retains 2,489 derivative shares in the form of outstanding stock options.
Outside of executive transactions, Personalis has highlighted significant operational developments. The company reported a first-quarter revenue beat, driven largely by its NeXT Personal minimal residual disease test. This test has experienced a 258% year-over-year growth rate and a 26% quarter-over-quarter increase. The platform is now utilized by over 1,000 oncologists, marking a significant adoption milestone.
Regulatory progress also features prominently in recent updates. Personalis secured expanded Medicare coverage for the NeXT Personal test. This approval permits the test's use in monitoring treatment response to neoadjuvant therapy for patients with specific types of breast cancer. It also allows for immunotherapy monitoring in patients with late-stage solid tumors.
Furthermore, the company received Class A CE-IVD marking for its EDTA and cfDNA Blood Collection Kits under the European Union's In Vitro Diagnostic Regulation. This approval enables the use of these kits in clinical trial sites across the European Union and Great Britain.
Corporate governance activities included the annual meeting of stockholders, where directors were elected and various proposals were approved. Meanwhile, BTIG adjusted its price target for Personalis from $13 to $11, while maintaining a Buy rating. This adjustment reflects BTIG's analysis of valuation dynamics within the broader lab sector.